Celyad Oncology SA CLYYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 0.59% | -127.00% | -0.43% | 226.28% | -7.85% |
| Total Depreciation and Amortization | -0.79% | 147.55% | 0.38% | -145.94% | 7.92% |
| Total Amortization of Deferred Charges | -- | -- | -0.58% | -- | -- |
| Total Other Non-Cash Items | 0.66% | 98.43% | 0.43% | -4,078.04% | 7.78% |
| Change in Net Operating Assets | 0.57% | 85.85% | 0.43% | -6,016.89% | 8.03% |
| Cash from Operations | 0.59% | 58.95% | 0.43% | -14.09% | -7.85% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -0.43% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -0.43% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00% | 27.40% | 0.00% |
| Issuance of Common Stock | -- | -- | 0.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -117.48% | 0.00% | 1,080.95% | 0.00% |
| Cash from Financing | 0.63% | -107.10% | -0.44% | 1,258.55% | -7.82% |
| Foreign Exchange rate Adjustments | 0.00% | -65.71% | 0.00% | 483.33% | 20.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | 0.00% | 200.00% | -20.00% |
| Net Change in Cash | 0.59% | -273.76% | -0.43% | 127.73% | -7.85% |